Literature DB >> 20677013

Susceptibility to chronic thromboembolic pulmonary hypertension may be conferred by miR-759 via its targeted interaction with polymorphic fibrinogen alpha gene.

Zhiyong Chen1, Toshiaki Nakajima, Nobuhiro Tanabe, Kunihiko Hinohara, Seiichiro Sakao, Yasunori Kasahara, Koichiro Tatsumi, Yoshinori Inoue, Akinori Kimura.   

Abstract

A deletion/insertion (Del/Ins) polymorphism of 28 base pairs (bp) in the 3' untranslated region (UTR) of fibrinogen alpha gene (FGA) was associated with thromboembolic diseases, but the underlying mechanisms remain unknown. Computational predication reveals that the 28 bp polymorphic fragment is complementary to the sequence of a microRNA, miR-759. In this study, we aim to investigate the association and implicated mechanisms between FGA polymorphisms and the susceptibility to chronic thromboembolic pulmonary hypertension (CTEPH). The Del/Ins polymorphism was analyzed in 190 patients with CTEPH and 628 controls. The FGA 3'UTR and miR-759 interaction was investigated using luciferase assay and quantitative RT-PCR method. Expression of miR-759 and FGA in human tissues was investigated by RT-PCR. The results reveal that the allele frequency of Ins was significantly higher in the patients than in the controls (55.8 vs. 47.1%, P=0.003, odds ratio=1.42, 95% confidence interval: 1.13-1.79). Both miR-759 and FGA were expressed in human liver. Co-transfection of miR-759 decreased the expression and mRNA stability of reporter gene containing the FGA 3'UTR. The effect of miR-759 was stronger on the Ins allele than on the Del allele. These observations suggest that the expression of FGA was regulated by miR-759 through its interaction at the polymorphic 3'UTR sequence, which was associated with the susceptibility to CTEPH.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20677013     DOI: 10.1007/s00439-010-0866-8

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  30 in total

1.  A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study.

Authors:  J Ma; C H Hennekens; P M Ridker; M J Stampfer
Journal:  J Am Coll Cardiol       Date:  1999-04       Impact factor: 24.094

2.  Nature of the fibrinogen Aalpha gene TaqI polymorphism.

Authors:  J A Remijn; R van Wijk; P G de Groot; W W van Solinge
Journal:  Thromb Haemost       Date:  2001-09       Impact factor: 5.249

Review 3.  Chronic thromboembolic pulmonary hypertension.

Authors:  Marius M Hoeper; Eckhard Mayer; Gérald Simonneau; Lewis J Rubin
Journal:  Circulation       Date:  2006-04-25       Impact factor: 29.690

4.  The alpha(E)C domain of human fibrinogen-420 is a stable and early plasmin cleavage product.

Authors:  D Applegate; L S Steben; K M Hertzberg; G Grieninger
Journal:  Blood       Date:  2000-04-01       Impact factor: 22.113

5.  alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism.

Authors:  A M Carter; A J Catto; H P Kohler; R A Ariëns; M H Stickland; P J Grant
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

6.  The alternatively spliced alpha(E)C domain of human fibrinogen-420 is a novel ligand for leukocyte integrins alpha(M)beta(2) and alpha(X)beta(2).

Authors:  V K Lishko; V P Yakubenko; K M Hertzberg; G Grieninger; T P Ugarova
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

7.  Associations between common fibrinogen gene polymorphisms and cardiovascular disease in older adults. The Cardiovascular Health Study.

Authors:  Cara L Carty; Mary Cushman; Daniel Jones; Leslie A Lange; Lucia A Hindorff; Kenneth Rice; Nancy S Jenny; J Peter Durda; Jeremy Walston; Christopher S Carlson; Debbie Nickerson; Russell P Tracy; Alex P Reiner
Journal:  Thromb Haemost       Date:  2008-02       Impact factor: 5.249

8.  The EC domains of human fibrinogen420 contain calcium binding sites but lack polymerization pockets.

Authors:  D Applegate; L Haraga; K M Hertzberg; L S Steben; J Z Zhang; C M Redman; G Grieninger
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

9.  Fibrinogen Aalpha-Thr312Ala and factor XIII-A Val34Leu polymorphisms in idiopathic venous thromboembolism.

Authors:  Grégoire Le Gal; Bénédicte Delahousse; Karine Lacut; Vincent Malaviolle; Sandra Regina; Marie-Thérèse Blouch; Francis Couturaud; Dominique Mottier; Emmanuel Oger; Yves Gruel
Journal:  Thromb Res       Date:  2007-06-12       Impact factor: 3.944

10.  HLA-DPB1 and NFKBIL1 may confer the susceptibility to chronic thromboembolic pulmonary hypertension in the absence of deep vein thrombosis.

Authors:  Satoshi Kominami; Nobuhiro Tanabe; Masao Ota; Taeko K Naruse; Yoshihiko Katsuyama; Norifumu Nakanishi; Hitonobu Tomoike; Masahito Sakuma; Kunio Shirato; Megumi Takahashi; Hiroki Shibata; Michio Yasunami; Zhiyong Chen; Yasunori Kasahara; Koichiro Tatsumi; Takayuki Kuriyama; Akinori Kimura
Journal:  J Hum Genet       Date:  2009-01-23       Impact factor: 3.172

View more
  13 in total

Review 1.  miRNAs: roles and clinical applications in vascular disease.

Authors:  Md Saha Jamaluddin; Sarah M Weakley; Lidong Zhang; Panagiotis Kougias; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Expert Rev Mol Diagn       Date:  2011-01       Impact factor: 5.225

Review 2.  MicroRNAs in respiratory disease. A clinician's overview.

Authors:  Derek Brown; Mohammad Rahman; S Patrick Nana-Sinkam
Journal:  Ann Am Thorac Soc       Date:  2014-10

3.  Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort.

Authors:  Marco Campos; Wei Sun; Fuli Yu; Maja Barbalic; Weihong Tang; Lloyd E Chambless; Kenneth K Wu; Christie Ballantyne; Aaron R Folsom; Eric Boerwinkle; Jing-Fei Dong
Journal:  Blood       Date:  2011-02-22       Impact factor: 22.113

4.  MicroRNA expression profile of pulmonary artery smooth muscle cells and the effect of let-7d in chronic thromboembolic pulmonary hypertension.

Authors:  Lei Wang; Li-Juan Guo; Jie Liu; Wang Wang; Jason X-J Yuan; Lan Zhao; Jun Wang; Chen Wang
Journal:  Pulm Circ       Date:  2013-12-05       Impact factor: 3.017

5.  Expression of microRNA-514a-5p and its biological function in experimental pulmonary thromboembolism.

Authors:  Yuanyuan Sun; Xingguo Zhang; Hua Gao; Mingjie Liu; Qi Cao; Xinyang Kang; Yusheng Wang; Ling Zhu
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

Review 6.  Discerning functional hierarchies of microRNAs in pulmonary hypertension.

Authors:  Vinny Negi; Stephen Y Chan
Journal:  JCI Insight       Date:  2017-03-09

7.  Differentially expressed plasma microRNAs and the potential regulatory function of Let-7b in chronic thromboembolic pulmonary hypertension.

Authors:  Lijuan Guo; Yuanhua Yang; Jie Liu; Lei Wang; Jifeng Li; Ying Wang; Yan Liu; Song Gu; Huili Gan; Jun Cai; Jason X-J Yuan; Jun Wang; Chen Wang
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

Review 8.  MicroRNAs and mesenchymal stem cells: hope for pulmonary hypertension.

Authors:  Zhaowei Zhu; Zhenfei Fang; Xinqun Hu; Shenghua Zhou
Journal:  Rev Bras Cir Cardiovasc       Date:  2015 Jul-Sep

9.  Regulation of coagulation factor XI expression by microRNAs in the human liver.

Authors:  Salam Salloum-Asfar; Raúl Teruel-Montoya; Ana B Arroyo; Nuria García-Barberá; Amarjit Chaudhry; Erin Schuetz; Ginés Luengo-Gil; Vicente Vicente; Rocío González-Conejero; Constantino Martínez
Journal:  PLoS One       Date:  2014-11-07       Impact factor: 3.240

10.  Aberrant expression of long noncoding RNAs in chronic thromboembolic pulmonary hypertension.

Authors:  Song Gu; Guanghui Li; Xitao Zhang; Jun Yan; Jie Gao; Xiangguang An; Yan Liu; Pixiong Su
Journal:  Mol Med Rep       Date:  2014-12-17       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.